标题
Optimizing Foundational Therapies in Patients With HFrEF
作者
关键词
-
出版物
JACC-Basic to Translational Science
Volume 7, Issue 5, Pages 504-517
出版商
Elsevier BV
发表日期
2022-03-03
DOI
10.1016/j.jacbts.2021.10.018
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A Novel Approach to Medical Management of Heart Failure with Reduced Ejection Fraction
- (2021) Robert JH. Miller et al. CANADIAN JOURNAL OF CARDIOLOGY
- 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
- (2021) Thomas M. Maddox et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
- (2021) Salim S. Virani et al. CIRCULATION
- Rapid Evidence‐Based Sequencing of Foundational Drugs for Heart Failure and a Reduced Ejection Fraction
- (2021) Milton Packer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Expediting the Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure—There Is No Time for Delay
- (2021) Gregg C. Fonarow et al. JAMA Cardiology
- Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
- (2021) David D. Berg et al. JAMA Cardiology
- CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
- (2021) Michael McDonald et al. CANADIAN JOURNAL OF CARDIOLOGY
- Patients profiling in Heart Failure for tailoring medical therapy A consensus document of the Heart Failure Association of the European Society of Cardiology
- (2021) Giuseppe M.C. Rosano et al. EUROPEAN JOURNAL OF HEART FAILURE
- Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
- (2021) João Pedro Ferreira et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed
- (2021) Stephen J. Greene et al. JAMA Cardiology
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
- (2021) Lauren A. Eberly et al. JAMA Network Open
- Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?
- (2021) Abhinav Sharma et al. CURRENT OPINION IN CARDIOLOGY
- Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study ( US , UK and Sweden)
- (2021) Gianluigi Savarese et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial
- (2021) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
- (2021) Ankeet S. Bhatt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
- (2021) Justin T. Parizo et al. JAMA Cardiology
- Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions
- (2020) Abhinav Sharma et al. CIRCULATION
- Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care
- (2020) Milton Packer EUROPEAN HEART JOURNAL
- Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
- (2020) Kieran F Docherty et al. EUROPEAN HEART JOURNAL
- Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials
- (2020) Muthiah Vaduganathan et al. LANCET
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- (2020) Paul W. Armstrong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing the cost‐effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real‐world evidence
- (2020) Phil McEwan et al. DIABETES OBESITY & METABOLISM
- Benefits of combination pharmacotherapy for HFrEF
- (2020) Gregory B. Lim Nature Reviews Cardiology
- Effect of sodium-glucose Cotransporter 2 inhibitors on cardiovascular and kidney outcomes – Systematic review and meta-analysis of randomized placebo-controlled trials
- (2020) Husam M. Salah et al. AMERICAN HEART JOURNAL
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
- (2020) Darren K. McGuire et al. JAMA Cardiology
- How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine
- (2020) John J.V. McMurray et al. CIRCULATION
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
- (2020) Piotr Ponikowski et al. LANCET
- Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective
- (2020) Subodh Verma et al. ESC Heart Failure
- Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice
- (2020) Muthiah Vaduganathan et al. JAMA Cardiology
- Longitudinal Titration of Medical Therapy for Heart Failure with Reduced Ejection Fraction: CHAMP-HF Registry
- (2019) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial
- (2019) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology
- (2019) Petar M. Seferovic et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure
- (2019) Abhinav Sharma et al. ESC Heart Failure
- Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF
- (2019) Adam D. DeVore et al. AMERICAN HEART JOURNAL
- Effect on Mortality of Higher vs Lower Beta Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients with Heart Failure
- (2018) Tarek Ajam et al. AMERICAN JOURNAL OF CARDIOLOGY
- Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology
- (2018) Maria G. Crespo-Leiro et al. EUROPEAN JOURNAL OF HEART FAILURE
- Medical Therapy for Heart Failure With Reduced Ejection Fraction
- (2018) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
- (2018) Thomas A. Zelniker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study
- (2018) Tiew-Hwa K Teng et al. Lancet Global Health
- Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges
- (2018) Catherine N. Marti et al. EUROPEAN JOURNAL OF HEART FAILURE
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
- (2018) Eric J. Velazquez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF
- (2017) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
- (2017) John J V McMurray et al. HEART
- Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyCLINICAL PERSPECTIVE
- (2016) Naoki Okumura et al. Circulation-Heart Failure
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy
- (2013) Henry Krum et al. Circulation-Heart Failure
- 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
- (2013) Clyde W. Yancy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
- (2009) Marvin A Konstam et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started